Boehringer Ingelheim Partners with MEDS to Enhance Access to Healthcare in Kenya
Boehringer Ingelheim and MEDS join forces to strengthen healthcare access
- Boehringer Ingelheim and MEDS sign a Memorandum of Understanding to enhance the impact of Boehringer Ingelheim’s ‘Access to Healthcare’ program.
- The collaboration aims to improve access to Boehringer Ingelheim’s leading type 2 diabetes and hypertension medications.
- Eligible patients will benefit from subsidized medications, reducing the financial burden of prevalent diseases and improving access to life-saving medication.
Boehringer Ingelheim, a renowned research-driven biopharmaceutical company, has recently partnered with Mission for Essential Drugs and Supplies (MEDS) to further expand the reach of Boehringer Ingelheim’s ‘Access to Healthcare’ program in Kenya. The primary objective of this partnership is to enhance access to affordable and life-saving medication for individuals battling type 2 diabetes and hypertension in the region while also strengthening the local healthcare infrastructure through strategic collaborations.
Empowering underserved communities through ‘Access to Healthcare’
The ‘Access to Healthcare’ program by Boehringer Ingelheim, launched in September 2022, is a comprehensive patient support initiative that aims to provide equitable healthcare access for underserved populations in Kenya. The program focuses on improving disease management, offering medical treatments at subsidized prices, and promoting patient adherence to medication for non-communicable diseases like hypertension and type 2 diabetes. Boehringer Ingelheim plans to expand this program across the region in the coming years to benefit more individuals in need.
Recent studies have shown that Non-Communicable Diseases (NCDs) account for a significant portion of all deaths in Kenya, highlighting the urgent need for initiatives like ‘Access to Healthcare’. Since its inception, the program has engaged over 200 physicians, enrolled more than 1,500 patients, and collaborated with 15 healthcare facilities in Kenya, making a notable impact on the local healthcare landscape.
Commitment to raising awareness and driving positive change
In addition to providing access to essential medications at subsidized rates, Boehringer Ingelheim and MEDS will collaborate on raising awareness about type 2 diabetes and hypertension through community campaigns. By educating the public about these conditions, the partners aim to encourage early diagnosis and treatment, ultimately improving the quality of life for patients in Kenya.
During the signing ceremony in Nairobi, Derek O’Leary, Regional Managing Director at Boehringer Ingelheim, emphasized the company’s dedication to providing quality healthcare for all individuals. He highlighted the significance of the partnership with MEDS in addressing the escalating burden of non-communicable diseases in Kenya and expressed optimism about the positive impact it will have on the local population.
Boehringer Ingelheim’s commitment to sustainable development and healthcare access is further exemplified through its ‘Sustainable Development for Generations’ framework. This framework aligns with the UN Sustainable Development Goals and aims to create value in areas of unmet medical need, enabling a healthier, more sustainable future for all. By 2030, Boehringer Ingelheim aims to expand access to healthcare for 50 million individuals in underserved communities, investing significantly in health innovation, research, and partnerships to combat diseases and improve healthcare outcomes.
The partnership between Boehringer Ingelheim and MEDS signifies a significant step towards enhancing healthcare access and driving positive change in Kenya. Through collaborative efforts and a shared commitment to improving patient outcomes, the two organizations are poised to make a lasting impact on the lives of individuals affected by type 2 diabetes and hypertension in the region.
